Pre-market Movers: HSCS, CALA, SNTI, RDBX, ACIU…

The following are some of the stocks making big moves in Thursday’s pre-market trading (as of 06.30 A.M. ET).

In the Green

Heart Test Laboratories, Inc. (HSCS) is up over 87% at $3.18
Senti Biosciences, Inc. (SNTI) is up over 19% at $2.45
Redbox Entertainment Inc. (RDBX) is up over 17% at $12.85
W&T Offshore, Inc. (WTI) is up over 9% at $8.00
Olympic Steel, Inc. (ZEUS) is up over 8% at $33.75

In the Red

Calithera Biosciences, Inc. (CALA) is down over 27% at $1.99
AC Immune SA (ACIU) is down over 15% at $2.42
Quantum Computing, Inc. (QUBT) is down over 9% at $2.36
Koninklijke Philips N.V. (PHG) is down over 8% at $20.78
Eros Media World Plc (EMWP) is down over 8% at $2.36
Symbotic Inc. (SYM) is down over 7% at $14.75
Tremor International Ltd (TRMR) is down over 7% at $8.61

Gold Prices Mixed As Dollar Steadies After Fed Meeting

Gold prices traded mixed on Thursday and the dollar regained its footing as the focus shifted back to concerns over the impact of surging inflation and an aggressive policy tightening.

Spot gold slipped 0.2 percent to $1,830.58 per ounce, while U.S. gold futures were up 0.7 percent at $1,832.70.

The dollar index rose slightly on risk aversion as the Fed-inspired rally faded and concerns about a potential contraction mounted.

After announcing a 75-basis point rate hike on Wednesday and leaving the door open for another rate increase of that magnitude in July, Fed Chair Jerome Powell said the central bank cannot control all the factors driving inflation.

Earlier today, the Swiss National Bank unexpectedly increased interest rates for the first time since 2007.

The monetary policy announcement from the Bank of England is due, with analysts expecting another 25-bps rate hike coupled with cautious commentary around the economy.

Pre-market Movers: SYM, FNCH, SGLY, SCKT, FRGE…

The following are some of the stocks making big moves in Thursday’s pre-market trading (as of 07.25 A.M. ET).

In the Green

Singularity Future Technology Ltd. (SGLY) is up over 14% at $4.35
Quantum Computing, Inc. (QUBT) is up over 12% at $3.87
Arbutus Biopharma Corporation (ABUS) is up over 11% at $2.99
Cognex Corporation (CGNX) is up over 10% at $52.86
Hemisphere Media Group, Inc. (HMTV) is up over 9% at $7.69
Celanese Corporation (CE) is up over 6% at $168.11
TG Therapeutics, Inc. (TGTX) is up over 5% at $5.31

In the Red

Symbotic Inc. (SYM) is down over 18% at $16.40
Finch Therapeutics Group, Inc. (FNCH) is down over 16% at $2.21
Socket Mobile, Inc. (SCKT) is down over 14% at $2.99
Forge Global Holdings, Inc. (FRGE) is down over 13% at $12.47
Bilibili Inc. (BILI) is down over 9% at $26.81
PDS Biotechnology Corporation (PDSB) is down over 9% at $3.63
Uranium Royalty Corp. (UROY) is down over 8% at $3.01
VivoPower International PLC (VVPR) is down over 8% at $2.06
Five Below, Inc. (FIVE) is down over 7% at $124.65

Ferrari Unveils 2022-2026 Plan

Ferrari (RACE) said it targets to achieve net revenues up to 6.7 billion euros in 2026, with a compounded annual growth rate of 9%, mainly driven by car-related activities. EBIT is projected to reach 1.8-2.0 billion euros by 2026, with a 27%-30% margin. In 2026, the company targets an EBITDA of 2.5-2.7 billion euros, with a CAGR of 11% that is greater than revenues, and an EBITDA margin of 38%-40%. Ferrari plans to generate a cumulated industrial free cash flow of 4.6-4.9 billion euros over the 2022-2026 period, doubled compared to 2016-2021.

Ferrari targets 15 new launches between 2023 and 2026. The first full electric Ferrari will be unveiled in 2025, the company noted. By 2026, the company targets a well-diversified product portfolio, composed of 60% hybrid and full electric and 40% ICE in terms of number of models. By 2030, the company is targeting an offering composed of 20% ICE, 40% hybrid and 40% full electric.

For 2022, the management is confident to meet at the high end of its guidance ranges, on the trajectory to the 2023 EBITDA targets of 1.8-2.0 billion euros.

Ferrari also decided to proceed with the proposal to increase the dividend pay-out for the following years to a steady 35% of adjusted net income, and to start a shares repurchase program of approximately 2 billion euros to be executed from now to the end of the plan period.

‘Brian and Charles’ Review: I, Robot Wearing a Cardigan

The comic performer David Earl plays a lonely inventor who builds a robot friend in this bionic buddy comedy.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Amy Nicholson

When you purchase a ticket for an independently reviewed film through our site, we earn an affiliate commission.

‘A Man of Integrity’ Review: Fighting Dirty

Mohammad Rasoulof’s scathing drama about corruption in Iran is striking in its blunt rage, if somewhat exasperating in its monotony.

Send any friend a story

As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.

By Devika Girish

When you purchase a ticket for an independently reviewed film through our site, we earn an affiliate commission.